Naporafenib

Drug identity checked against registry records

Also recorded as ERAS-254; LXH254

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)NCT06346067ERASPhase 3Active not recruiting2028-04Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.